News >

R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma

Jason Harris
Published: Friday, Nov 03, 2017

mcl
According to phase III results from the FOLL05 trial, the combination of rituximab (Rituxan) plus cyclophosphamide, vincristine, and prednisone (R-CVP) produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma (FL).

“This long-term update of the FOLL05 trial confirms the high efficacy of [immunochemotherapy] ICT for the initial treatment of patients with advanced-stage FL in need of therapy,” investigators wrote. “In addition, with the longer follow-up, we can conclude that if the aim of initial therapy is to maximize treatment activity and increase the chance of durable disease control, R-CHOP should be the preferred option among the 3 regimens.”
Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma [published online ahead of print November 2, 2017]. J Clin Oncol. 2017. doi: 10.1200/JCO.2017.74.1652

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x